Use of genetic instability to predict biochemical recurrence in intermediate-risk prostate cancer

被引：0
|
作者：
Bristow, R. G.
Ishkanian, A. S.
Malloff, C.
Milosevic, M.
Pintilie, M.
van der Kwast, T.
Lam, W.
机构：
[1] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[2] Univ Toronto, Toronto, ON, Canada
[3] British Columbia Canc Res Ctr, Vancouver, BC V5Z 1L3, Canada
[4] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 07期
关键词：
D O I：
10.1200/jco.2011.29.7_suppl.42
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
42
引用
收藏
页数：1
相关论文
共 50 条
  • [41] INTERMEDIATE-RISK PROSTATE CANCER, ANDROGEN DEPRIVATION THERAPY AND THE RISK OF DEATH
    Pickles, Tom
    Tyldesley, Scott
    Keyes, Mira
    Morris, W. James
    RADIOTHERAPY AND ONCOLOGY, 2016, 120 : S27 - S27
  • [42] Brachytherapy for Intermediate-Risk Prostate Cancer, Androgen Deprivation, and the Risk of Death
    Pickles, Tom
    Tyldesley, Scott
    Hamm, Jeremy
    Virani, Sean A.
    Morris, W. James
    Keyes, Mira
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 100 (01): : 45 - 52
  • [43] Positive surgical margins are a risk factor for significant biochemical recurrence only in intermediate-risk disease
    Corcoran, Niall M.
    Hovens, Chris M.
    Metcalfe, Charles
    Hong, Matthew K. H.
    Pedersen, John
    Casey, Rowan G.
    Peters, Justin
    Harewood, Laurence
    Goldenberg, S. Larry
    Costello, Anthony J.
    Gleave, Martin E.
    BJU INTERNATIONAL, 2012, 110 (06) : 821 - 827
  • [44] Very long-term biochemical and dosimetric outcomes of LDR boost in intermediate-risk prostate cancer
    Goni Ramirez, A.
    De Paula Carranza, B.
    Pastor Sanchis, V.
    Bartres Salido, A.
    de Urturi Albisu, E. Saenz
    Bulto Boque, N.
    Eguiguren Bastida, M.
    Pagola Divasson, M.
    Ayete, A.
    de Urbina Ugarte, D. Ortiz
    Suarez, N.
    Erzilbengoa, M.
    Rosa Nieto, J.
    RADIOTHERAPY AND ONCOLOGY, 2021, 158 : S125 - S126
  • [45] Using NBN to predict biochemical relapse following image-guided radiotherapy (IGRT) for intermediate-risk prostate cancer (IR-PCa)
    Berlin, Alejandro
    Lalonde, Emilie
    Zafarana, Gaetano
    Sykes, Jenna
    Ramnarine, Varune Rohan
    Lam, Wan
    Meng, Alice
    Milosevic, Michael
    van der Kwast, Theodorus
    Boutros, Paul C.
    Bristow, Robert Glen
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [46] Do Testosterone Kinetics After Radiation Therapy (RT) Predict Biochemical Failure (BCF) for Low- and Intermediate-risk Prostate Cancer (CaP)?
    Martin, J. M.
    Sopka, D. M.
    Ruth, K. J.
    Buyyounouski, M. K.
    Kutikov, A.
    Sobczak, M. L.
    Chen, D. Y.
    Horwitz, E. M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03): : S185 - S186
  • [47] Is active surveillance safe for patients with intermediate-risk prostate cancer?
    Chung, Hoseok
    Shin, Bo Sung
    Nam, Deok-Hyun
    Chung, Hoseok
    Kim, Myung Ki
    Jung, Seung Il
    Kang, Taek Won
    Kwon, Dong Deuk
    BJU INTERNATIONAL, 2015, 116 : 4 - 4
  • [48] Active surveillance for intermediate-risk prostate cancer: yes, but for whom?
    Overland, Maya R.
    Washington, Samuel L., III
    Carroll, Peter R.
    Cooperberg, Matthew R.
    Herlemann, Annika
    CURRENT OPINION IN UROLOGY, 2019, 29 (06) : 605 - 611
  • [49] Predicting intermediate-risk prostate cancer using machine learning
    Stojadinovic, Miroslav
    Stojadinovic, Milorad
    Jankovic, Slobodan
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2025, : 1737 - 1746
  • [50] Is there a need for supplemental XRT in intermediate-risk prostate cancer patients?
    Stone, Nelson N.
    BRACHYTHERAPY, 2013, 12 (05) : 393 - 397
12345